Accretion Pharmaceuticals Limited (NSE:ACCPL)
India · Delayed Price · Currency is INR 215.00
+5.00 (2.38%)
At close: Sep 11, 2026
Accretion Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 96.68 | 67.94 | 14.93 | 1.04 | 0.79 |
Depreciation & Amortization | 12.11 | 7.75 | 2.24 | 9.23 | 8.1 |
Other Operating Activities | 10.12 | 16.3 | 16.9 | 10.76 | 10.35 |
Change in Accounts Receivable | -107.39 | -58.57 | -70.47 | -17.31 | 12.55 |
Change in Inventory | -77.65 | -61.34 | -144.76 | -8.31 | -19.75 |
Change in Accounts Payable | -18.21 | 10.09 | 66.08 | 11.12 | 5.71 |
Change in Other Net Operating Assets | -61.01 | 11.65 | - | -3.32 | 3.74 |
Operating Cash Flow | -145.34 | -6.19 | -115.09 | 3.21 | 21.5 |
Operating Cash Flow Growth | - | - | - | -85.06% | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -85.34 | -16.11 | -54.78 | -11.78 | -2.57 |
Sale of Property, Plant & Equipment | - | - | - | 0.79 | - |
Investing Cash Flow | -85.34 | -16.11 | -54.78 | -11 | -2.57 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | - | 63.69 | - | - | - |
Long-Term Debt Issued | - | - | 134.78 | 8.58 | - |
Total Debt Issued | - | 63.69 | 134.78 | 8.58 | - |
Short-Term Debt Repaid | -14.77 | - | - | - | - |
Long-Term Debt Repaid | -3.05 | -57.43 | - | - | -2.81 |
Total Debt Repaid | -17.82 | -57.43 | - | - | -2.81 |
Net Debt Issued (Repaid) | -17.82 | 6.26 | 134.78 | 8.58 | -2.81 |
Issuance of Common Stock | 297.55 | 30 | 40 | 6.59 | - |
Repurchase of Common Stock | - | - | - | - | -2.87 |
Other Financing Activities | -9.34 | -14.37 | -3.99 | -10.76 | -10.17 |
Financing Cash Flow | 270.38 | 21.89 | 170.79 | 4.4 | -15.85 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | -0 | - | - | - | -0 |
Net Cash Flow | 39.7 | -0.41 | 0.92 | -3.38 | 3.08 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -230.68 | -22.3 | -169.87 | -8.57 | 18.93 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -25.74% | -3.89% | -127.22% | -2.90% | 8.38% |
Free Cash Flow Per Share | -21.55 | -2.78 | -22.35 | - | - |
Levered Free Cash Flow | -230.22 | -44.15 | -111.16 | -19.15 | - |
Unlevered Free Cash Flow | -225.6 | -35.48 | -109.56 | -12.74 | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 9.34 | 14.37 | 3.99 | 10.76 | 10.17 |
Cash Income Tax Paid | 33.38 | 27.77 | -7.89 | 0.35 | 0.07 |
Change in Working Capital | -264.25 | -98.17 | -149.15 | -17.82 | 2.26 |